Frost & Sullivan awards Fu Kang (Shanghai) Health Tech Co., Ltd. the 'China AI Drug R&D Innovation Award'

Frost & Sullivan grants to Fookang (Shanghai) HealthTech Co., Ltd.

"China AI Drug R&D Innovation Award"

Dr. Wang Xin presented the award to Dr. Shen Xiaokun of Fukan Pharmaceutical

Fukang Pharmaceutical is a new drug R&D enterprise based in China and targeting the global market. With the vision of developing breakthrough therapies, it is committed to developing innovative drugs in the fields of oncology, virology, and aging diseases. The company is guided by the unmet clinical medication needs in China and globally, designing and developing original innovative drugs with 'First-in-Class' or 'Best-in-Class' potential to provide innovative treatment options for patients.

The Right-6D principle mainly refers to focusing on the correct target definition (Right Target define), the correct tissue delivery (Right Tissue deliver), the correct safety outcome guidance (Right Safety drive), the correct patient documentation (Right Patient document), the correct combination design (Right Combination design), and the correct implementation of commercial potential (Right Commercial Potential deploy). The company's highly selective PI3KB/δ inhibitor and second-generation PARP inhibitors, among other innovative drugs, can meet clinical needs and enable more patients to benefit clinically. At the same time, combined with AI technology platforms, predictions are made on protein structure, binding modes, and pharmaceutical properties. The Fukeang Excellence Center's medicinal chemistry team has applied AIDD technology in the optimization of lead compounds, advancing several product pipelines into preclinical research.

In addition to its own technical accumulation and accelerating the construction of an AI new drug R&D innovation technology platform, FuKang Pharmaceutical has also joined hands with many AI companies such as DeepSight Technology to continuously explore new technologies and methods. At the same time, the company also places great emphasis on commercialization capabilities. By signing commercialization cooperation agreements with companies such as Fosun Pharma, Jiuzhou Tong, and Sinovac Biotech, and utilizing the strong domestic and international sales networks of partners, the company promotes a globalization strategy.

To create an open research ecosystem, Fukang Pharmaceutical has been continuously collaborating with renowned universities, research institutes, and AI companies at home and abroad, achieving fruitful results. For example, in 2020 and 2021, urgent research breakthroughs with multiple teams including Tsinghua University and Jiangsu Provincial CDC were published in well-known SCI journals. In 2022, a joint laboratory was established with Shenshi Technology. Researchers from Fukang Pharmaceutical's Excellence Center combined Shenshi Technology's unique Uni-Fold function for protein structure prediction, Uni-Docking function for lead compound screening, and Uni-FEP function for lead compound optimization into multiple modules to build a new generation of drug computational design platform. This platform mainly utilizes various leading AI algorithms such as Hermite®, continuously strengthening the construction of new drug research and development technology platforms. At the same time, Fukang Pharmaceutical uses the Uni-Mol3D molecular pre-training model to model, generate, evaluate, and screen a series of scaffold molecules, obtaining a high-quality virtual compound library for specific targets and high-quality systems. Taking the H84 project as an example, with the support of AlDD technology, Fukang's Excellence Center's medicinal chemistry team synthesized less than 80 molecules from 2 lead compounds within half a year, obtaining targeted anti-tumor drugs with good pharmacological properties. Currently, the project has entered preclinical research. Thanks to the application of AIDD technology in lead compound optimization, research and development costs have been effectively saved. This is one of the important milestones in the implementation process of Fukang Pharmaceutical's Right 6D new drug research and development strategy combined with AI technology platforms.

Fukang Pharmaceutical is oriented towards developing products to meet unmet clinical medication needs in China and globally, forming a competitive portfolio of first-in-class and best-in-class anti-tumor research and development pipelines. It has a differentiated positioning in the selection of product pipeline indications, for example, when deploying the small molecule tyrosine kinase inhibitor CVL009, it focuses on potential indications for unapproved EGFR rare mutations in NSCLC; the PI3Kβ/δ dual inhibitor CVL237 is developed primarily for PTEN mutant solid tumors and BTK-resistant cases.